Is there a role for aspirin in metabolic dysfunction-associated steatotic liver disease (MASLD) and the relationship to Psoriasis?

Interdisciplinary medicine is an important concept in patient-centered medical care. How can we apply concepts from new research to improve patient care through both education and collaboration with our patients and their care team?

It is well known that having psoriasis increases the risk of developing metabolic syndrome. Non-alcoholic fatty liver disease (NAFLD) is a component of metabolic syndrome.  Fatty liver disease is associated with an increased risk of liver inflammation and fibrosis.

Recently Chan et al., completed a study showing that low-dose aspirin (81 mg) was effective in decreasing hepatic fat compared to placebo (untreated arm) at six months.  In addition, the aspirin treated group also showed decreases in laboratory values for AST and ALT.  Thus, patients with psoriasis and/or metabolic syndrome should discuss these findings with their care team to determine if this therapy would be appropriate for them.

References:

1. Wenk K, Arrington K, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol. 2011;25:383–91.

2. Simon TG, Wilechansky RM, Stoyanova S, Grossman A, Dichtel LE, Lauer GM, Miller KK, Hoshida Y, Corey KE, Loomba R, Chung RT, Chan AT. Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial. JAMA. 2024 Mar 19;331(11):920-929. doi: 10.1001/jama.2024.1215.